Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Blue Cross NC updates Tocilizumab utilization criteria to prefer Tyenne, effective January 1, 2025 November 07, 2024 Pharmacy

As of January 1, 2025, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will update its Tocilizumab utilization criteria to prefer Tyenne®. Actemra® will be removed from preferred status.

To ensure a smooth transition, patients with a current Actemra prior authorization approval may transition to the preferred product (Tyenne) on January 1, 2025, without requirement of an additional prior authorization at that time. Initial Tyenne prior authorizations will be active through the original Actemra prior authorization approval date. An additional prior authorization will be required after January 1, 2025, to continue Actemra therapy.

Requests for continuation of Actemra will not be able to be reviewed until after January 1, 2025. Please submit all requests through Blue e for fastest processing times.

Learn more about Tocilizumab (Actemra®) and Tocilizumab Biosimilars.